Finally, data on 10 years of genetic testing (November 1996 to March 2006) conducted by Myriad Laboratory (USA), representing more than 95% of genetic testing for BRCA1/BRCA2 genes performed in the United States, not-selected by breast/ovarian cancer family history, points to a frequency of 12.5% identified deleterious mutations (5,780 mutated individuals in a total of 46.276 individuals consecutively tested) [30]. This evidence concerns the gene BRCA2 and ovarian carcinoma.